But the deal will most likely face heavy scrutiny from regulators, TheStreet's Jim Cramer said on CNBC's "Squawk on the Street" this morning
"These guys are way too confident," Cramer said of the companies. "They don't know this Justice Department."
He explained that anti-trust regulators have blocked a number of recent deals, such as the proposed merger between Halliburton (HAL) and Baker Hughes (BHI) earlier this month.
TheStreet.com compiled data that essentially show this is the most activist antitrust department, Cramer added in the above video.
"I think the lawyers haven't read the package that we put together because if they did, they'd know this thing ain't happening," he said.
Also, disagreements between rival health insurers Cigna (CI) and Anthem (ANTM) could similarly derail antitrust approvals for Anthem's $48 billion proposed acquisition, sources told the Wall Street Journal.
Competitor UnitedHealth Group (UNH) has gotten out of the Affordable Care Act health insurance exchanges since it isn't concerned with government approval, and the company has "blown away numbers," Cramer mentioned.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Monsanto's strengths such as its expanding profit margins and notable return on equity outweigh the fact that the company has had lackluster performance in the stock itself.
You can view the full analysis from the report here: MON
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.